Search | Clinical Trials Finder

Conditions: Insomnia, Insomnia Chronic
Interventions: Zolpidem tartrate; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 40 Years to 85 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Risk Reduction Behavior, Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions: Family-focused intervention arm, Individual-focused intervention arm; Behavioral
Lead sponsor: Gia Mudd; Other
Eligibility: 18 Years and older
Enrollment: 526 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Alcohol Drinking, Alcohol Intoxication
Interventions: Alcohol; Drug
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 21 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Champaign, Illinois

Conditions: Juvenile Idiopathic Arthritis Associated Uveitis, Uveitis, Anterior
Interventions: Adalimumab/Biosimilar; Biological
Lead sponsor: Nisha Acharya; Other
Eligibility: 2 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 9
States / cities: Los Angeles, California • Sacramento, California • San Francisco, California + 6 more

Conditions: HIV Infections
Interventions: PGDM1400LS (5mg/kg, IV), PGDM1400LS (20mg/kg, IV), PGDM1400LS (20mg/kg, SC), PGDM1400LS (40mg/kg, IV), PGDM1400LS (40mg/kg, SC), PGDM1400LS (1.4g, IV), PGDM1400LS (1.4g, SC), VRC07-523LS (20mg/kg, IV), VRC07-523LS (20mg/kg, SC), VRC07-523LS (1.4g, IV), VRC07-523LS (1.4g, SC), VRC07-523LS (40mg/kg, IV), PGT121.414.LS (20mg/kg, IV), PGT121.414.LS (20mg/kg, SC), PGT121.414.LS (1.4g, IV), PGT121.414.LS (1.4g, SC), PGT121.414.LS (40mg/kg, IV); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more

Conditions: Dietary Habits, Health Behavior, Eating Behavior
Interventions: Behavioral Gardening Exposure, Healthy Eating and Gardening Curriculum; Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 8 Years to 12 Years
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Farmington, New Mexico • Seattle, Washington

Conditions: HIV-1-infection
Interventions: DV700P-RNA, DV701B1.1-RNA; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 5 more

Conditions: Rehabilitation, Recovery of Function, Stroke
Interventions: Duck Duck Punch Play, Commercially Available Game Play; Device · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years to 90 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Quercetin; Drug
Lead sponsor: Temple University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetic; Neuropathic, Polyneuropathy (Manifestation)
Interventions: 3% oxybutynin, Placebo; Drug
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 30 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Auto-Brewery Syndrome, Gut Fermentation Syndrome
Interventions: Fecal microbiota transplantation capsules; Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: carboplatin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Coronary Atherosclerosis, Endothelial Dysfunction
Interventions: Blood sampling from the Coronary Sinus and Aorta, Intravascular Ultrasound of the coronary artery.; Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Major Depressive Disorder (MDD)
Interventions: Nicotine transdermal patch, PET Scan with [18F] VAT; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Breast Cancer
Interventions: Yoga Group, Stretching Control Group, Waitlist Control Group, Questionnaire; Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Low Bone Mass
Interventions: Resveratrol, Placebo; Dietary Supplement
Lead sponsor: University of Delaware; Other
Eligibility: Female only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Melanoma
Interventions: Eviderma Smart Phone Teledermatology Application (Eviderma); Other
Lead sponsor: Northwestern University; Other
Eligibility: 16 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: 2009 H1N1 Influenza
Interventions: Live Attenuated H1N1 Influenza Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live; Biological
Lead sponsor: University of Rochester; Other
Eligibility: 4 Years to 9 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Memory Impairment
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 45 Years to 70 Years
Enrollment: 139 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Nephrolithiasis, Hyperoxaluria, Crohn's Disease
Interventions: Oxadrop, Agri-King Synbiotic (AKSB), Placebo; Dietary Supplement · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Smoking
Interventions: Smoking Abstinence; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Bipolar I Disorder
Interventions: Lithium treatment in combination with a SGA (Second Generation Antipsychotic), Placebo/Adjunctive SGA treatment; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 12 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Lupus Erythematosus, Systemic, Systemic Vasculitis, Isolated Angiitis of Central Nervous System, Lung Disease With Systemic Sclerosis, Lung Disease Interstitial Diffuse
Interventions: depot leuprolide acetate 3.75 mg, Placebo; Drug
Lead sponsor: Joseph Mccune; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Columbus, Ohio

Conditions: Non-Alcoholic Fatty Liver Disease, Obesity
Interventions: Fructose Solution (75 Grams), Glucose Solution (75 grams); Other
Lead sponsor: Rockefeller University; Other
Eligibility: 45 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Partial Reinforcement II: Three Approaches to Maintenance Therapy for Chronic Insomnia

Corazon de la Familia (Heart of the Family)

Towards a Wearable Alcohol Biosensor: Examining the Accuracy of BAC Estimates From New-Generation Transdermal Technology Using Large-Scale Human Testing and Machine Learning Algorithms

Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial

A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult Participants

Yeego! Healthy Eating & Gardening School-Based Randomized Controlled Trial

A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1-RNA in Adults Without HIV

Functional Viability Duck Duck Punch

Biological Effects of Quercetin in COPD

Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy

Fecal Microbiota Transplant for Autobrewery Syndrome

Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer

Lp-PLA2 and Coronary Atherosclerosis in Humans

PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.

Effects of Yoga in Breast Cancer Patients

Resveratrol for the Prevention of Bone Loss in Postmenopausal Women

Teaching Skin Self-Examination to First-degree Relatives of Melanoma Patients Using Mobile App Technology

Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children

Age-related Longitudinal Changes in Aviator Performance

Use of Oral Probiotics to Reduce Urinary Oxalate Excretion

Neuroimaging Decision Making and Response Inhibition During Smoking Abstinence

Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania

GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases

Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot Study